NCT02723994: An ongoing trial by Incyte Corporation
This trial is ongoing. It must report results 10 months, 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT02723994 |
|---|---|
| Title | A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 30, 2016 |
| Completion date | March 3, 2026 |
| Required reporting date | March 3, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |